{"id":"gnrhr","name":"GnRH receptor (GNRHR)","symbol":"GNRHR","route":"/targets/gnrhr/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4421","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109163","uniprot":"https://www.uniprot.org/uniprotkb/P30968/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P30968","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1855","open-targets":"https://platform.opentargets.org/target/ENSG00000109163","civic":"https://civicdb.org/genes/2798/summary","oncokb":"https://www.oncokb.org/gene/GNRHR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GNRHR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=GNRHR","depmap":"https://depmap.org/portal/gene/GNRHR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000109163-GNRHR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2798","omim":"https://www.omim.org/entry/138850"}],"products":[{"id":"abarelix","name":"Abarelix","status":"withdrawn","modality":"GnRH antagonist peptide, intramuscular depot","route":"/drugs/abarelix/"},{"id":"buserelin","name":"Buserelin","status":"established","modality":"GnRH agonist, injection or nasal spray","route":"/drugs/buserelin/"},{"id":"histrelin","name":"Histrelin","status":"established","modality":"GnRH agonist, twelve-month subcutaneous implant","route":"/drugs/histrelin/"}],"trials":[{"id":"nct00567580","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","nct":"NCT00567580","phase":"3","status":"positive"},{"id":"nct00936390","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","nct":"NCT00936390","phase":"3","status":"completed"},{"id":"nct00002633","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","nct":"NCT00002633","phase":"3","status":"completed"},{"id":"nct00841113","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","nct":"NCT00841113","phase":"3","status":"completed"},{"id":"nct00003653","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","nct":"NCT00003653","phase":"3","status":"completed"},{"id":"nct03678025","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","nct":"NCT03678025","phase":"3","status":"recruiting"},{"id":"nct01394263","name":"Study of Histrelin Subdermal Implant in Patients With Prostate Cancer","nct":"NCT01394263","phase":"3","status":"completed"},{"id":"nct01697384","name":"Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer","nct":"NCT01697384","phase":"3","status":"completed"},{"id":"nct04513717","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","nct":"NCT04513717","phase":"3","status":"active"},{"id":"nct00100243","name":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","nct":"NCT00100243","phase":"2","status":"completed"}],"pathways":[],"companies":["endo","sanofi","tolmar","verity-pharma"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}